1-methyl-3-phenylindene ozonide | 256530-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-methyl-3-phenylindene ozonide
• 英文别名: 4,5-Dihydro-5-methyl-1-phenyl-1,4-epoxy-1h-2,3-benzodioxepin；8-methyl-1-phenyl-10,11,12-trioxatricyclo[7.2.1.02,7]dodeca-2,4,6-triene
• CAS: 256530-40-2
• 化学式: C₁₆H₁₄O₃
• 分子量: 254.285
• InChiKey: YQIFBMUISTUWJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-3-phenylindene ozonide 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以12%的产率得到1-(2-苯甲酰氧基苯基)丙醛
  参考文献：
  名称：

  Synthesis, x-ray analysis, and acidolysis of exo- and endo-1-methylindene ozonides

  摘要：

  DOI：

  10.1021/ja00346a051
• 作为产物：
  描述：

  1-methyl-3-phenylindene 在 臭氧 作用下， 生成 1-methyl-3-phenylindene ozonide
  参考文献：
  名称：

  Formation of the crossed product 1,4-disubstituted 2,3,5,6,11-pentaoxabicyclo[5.3.1]undecane from a mixture of two kinds of ozonides in the presence of an acid catalyst. Elucidation of the intermediates in the acidolysis of an ozonide

  摘要：

  DOI：

  10.1021/ja00397a034

文献信息

• Ozonide compounds with inhibitory activity for urokinase production and angiogenesis
  申请人：Taiho Pharmaceutical Company Ltd.

  公开号：US06365610B1

  公开（公告）日：2002-04-02

  The invention provides a urokinase production inhibitor or angiogenesis inhibitor comprising as an active component an ozonide derivative represented by the formula (1), and method of prevention or therapy using the inhibitor wherein A is an oxygen atom or N—R (wherein R is phenyl or phenyl having as a substituent lower alkyl having 1 to 6 carbon atoms, lower alkoxyl having 1 to 6 carbon atoms or a halogen atom); B is an oxo group or —R4; and (1) when A is an oxygen atom, R1 is a hydrogen atom, etc., R2 is phenyl, etc., R3 is a hydrogen atom, etc., B is an oxo group or —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.; (2) when A is N—R, R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., B is —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.

  本发明提供了一种尿激酶制剂或血管生成抑制剂，其包括以式（1）表示的臭氧化物衍生物作为活性成分，并提供使用该制剂的预防或治疗方法，其中A为氧原子或N-R（其中R为苯基或具有取代的较低烷基，其具有1至6个碳原子，较低烷氧基，其具有1至6个碳原子或卤素原子）; B是氧代基或-R4; 当A是氧原子时，R1是氢原子等，R2是苯基等，R3是氢原子等，B是氧代基或-R4，R4是氢原子等，R5是氢原子等；当A是N-R时，R1是氢原子等，R2是氢原子等，R3是氢原子等，B是-R4，R4是氢原子等，R5是氢原子等。
• UROKINASE PRODUCTION INHIBITORS, ANGIOGENESIS INHIBITORS AND METHODS OF PREVENTION OR TREATMENT WITH BOTH
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1033130A1

  公开（公告）日：2000-09-06

  The invention provides a urokinase production inhibitor or angiogenesis inhibitor comprising as an active component an ozonide derivative represented by the formula (1), and method of prevention or therapy using the inhibitor wherein A is an oxygen atom or N-R (wherein R is phenyl or phenyl having as a substituent lower alkyl having 1 to 6 carbon atoms, lower alkoxyl having 1 to 6 carbon atoms or a halogen atom); B is an oxo group or -R4; and (1) when A is an oxygen atom, R1 is a hydrogen atom, etc., R2 is phenyl, etc., R3 is a hydrogen atom, etc., B is an oxo group or -R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.; (2) when A is N-R, R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., B is -R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.

  本发明提供了一种尿激酶生成抑制剂或血管生成抑制剂，其活性成分包括由式(1)表示的臭氧衍生物，以及使用该抑制剂进行预防或治疗的方法 其中 A 是氧原子或 N-R(其中 R 是苯基或具有 1 至 6 个碳原子的低级烷基、具有 1 至 6 个碳原子的低级烷氧基或卤原子作为取代基的苯基)；B 是氧代基团或 -R4；以及 (1) 当 A 是氧原子时，R1 是氢原子等，R2 是苯基等、R3 是氢原子等，B 是氧代基团或-R4，R4 是氢原子等，R5 是氢原子等；(2) 当 A 是 N-R，R1 是氢原子等，R2 是氢原子等，R3 是氢原子等，B 是-R4，R4 是氢原子等，R5 是氢原子等。
• MIURA MASAHIRO; NOJIMA MASATOMO; KUSABAYASHI SHIGEKAZU; NAGASE SHIGERU, J. AMER. CHEM. SOC., 1981, 103, NO 7, 1789-1796
  作者：MIURA MASAHIRO、 NOJIMA MASATOMO、 KUSABAYASHI SHIGEKAZU、 NAGASE SHIGERU

  DOI：——

  日期：——
• INHIBITOR OF UROKINASE PRODUCTION AND OF ANGIOGENESIS AND ITS THERAPEUTIC USE
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1033130B1

  公开（公告）日：2004-04-21
• US6365610B1
  申请人：——

  公开号：US6365610B1

  公开（公告）日：2002-04-02